Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: Results of the Australian patients treated on phase II trials

Australasian Journal of Dermatology

Volumn 42, Issue 2, 2001, Pages 91-97

  Miles Prince, H ^a   McCormack, Christopher ^b   Ryan, Gail ^a   Baker, Christopher ^b   Rotstein, Harvey ^b   Davison, Jill ^a   Yocum, Richard ^c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

Mycosis fungoides; Oral; Retinoid; Topical

Indexed keywords

ALPHA INTERFERON; ATORVASTATIN; BEXAROTENE; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; PREDNISOLONE; THYROTROPIN; TRIACYLGLYCEROL; VINCRISTINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUSTRALIA; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG CAPSULE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EAR DISEASE; EDEMA; FEMALE; GEL; HEADACHE; HUMAN; HYPERTRIGLYCERIDEMIA; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN LYMPHOMA; T CELL LYMPHOMA;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; ANTICARCINOGENIC AGENTS; AUSTRALIA; CAPSULES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GELS; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; SKIN NEOPLASMS; SURVIVAL RATE; TETRAHYDRONAPHTHALENES; TREATMENT OUTCOME;

EID: 0035025231     PISSN: 00048380     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-0960.2001.00488.x     Document Type: Article

References (33)

1. Siegel RS, Pandolfino T, Guitart J, Rosen S, Kuzel TM. Primary cutaneous T-cell lymphoma: Review and current concepts. J. Clin. Oncol. 2000; 18: 2908-25.
2. Zackheim HS, Amin S, Kashani-Sabet M, McMillan A. Prognosis in cutaneous T-cell lymphoma by skin stage: Long-term survival in 489 patients. J. Am. Acad. Dermatol. 1999; 40: 418-25.
3. Rosen ST, Foss FM. Chemotherapy for mycosis fungoides and the Sezary syndrome. Haematol Oncol Clin. Nth. Am. 1995; 5: 1109-16.
4. Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sezary syndrome. Blood 1996; 88: 2385-409.
5. Kuzel TM, Hurria A, Samuelson E, Tallman MS, Roenigk Jr HH, Radernaker MS, Rosen ST. Phase II trial of 2-chlordeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood 1996; 87: 906-11.
6. Matutes ME, Deardon C, MacLennan K, Catovsky D. The role of pentostatin in the treatment of T-cell malignancies: Analysis of response rate in 145 patients according to disease subtype. J. Clin. Oncol. 1994; 12: 2588-93.
7. Roenigk HH, Kuzel TM, Skontelis AP, Springer E, Yu G, Caro W et al. Photochemotherapy alone or combined with Interferon 2 alpha in the treatment of cutaneous T-cell lymphoma. J. Invest Dermatol. 1990; 95(S.6): S198-205.
8. Wollina U, Graefe T, Karte K. Treatment of relapsing and recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. J. Am. Acad. Dermatol. 2000; 42: 40-6.
9. Zinzani PL, Baliva G, Magagnoli M, Bendandi M, Modugno G, Gherlinzoni F, Orcioni GF, Ascani S, Simoni R, Pileri SA et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: Experience in 44 patients. J. Clin. Oncol. 2000; 18: 2603-6.
10. Kaye FJ, Bunn Jr PA, Steinberg SM, Stockler JL, Ihde DC, Fischmann AB, Glatstein EJ, Phelps RM, Foss FM, Parlette III HL et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N. Engl. J. Med. 1989; 321: 1784-90.
11. Warrell Jr RP, Coonley CJ, Kempin SJ, Myskowski P, Safai B, Itri LM. Isotretinoin in cutaneous T-cell lymphoma. Lancet 1983; 2: 629.
12. Neely SM, Mehlmauer M, Feinstein DI. The effect of isotretinoin in six patients with cutaneous T-cell lymphoma. Arch. Intern. Med. 1987; 147: 529-31.
13. Kessler JF, Jones SE, Levine N, Lynch PJ, Booth AR, Myskens FLJ, Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch. Dermatol. 1987; 123: 201-4.
14. Fitzpatrick JE, Mellette JR. Treatment of mycosis fungoides with isotretinoin. J. Dermatol. Surg. Oncol. 1986; 12: 626-9.
15. Molin L, Thomsen K, Volden G, Aronsson A, Hammar H, Hellbe L, Roupe G. Oral retinoids in mycosis fungoides and Sezary syndrome: A comparson of isotretinoin and etretinate. Acta Derm. Venereal. 1987; 67: 232-6.
16. Thomsen K, Molin L, Volden G, Lang Wantzin G, Hellbe L, 13-Cis-retinoic acid effective in mycosis fungoides. A report from the Scandanavian Mycosis Fungoides Group. Acta Derm. Venereol. 1984; 64: 563-6.
17. Kessler JF, Jones SE, Levine N, Lynch PJ, Booth AR, Meyskens FL, Isotretinoin and cutaneous T-cell lymphoma. Arch. Dermatol. 1987; 123: 232-6.
18. Thomsen K, Hammar H, Molin L, Volden G. Retinoids plus PUVA and PUVA in mycosis fungoides, plaque stage. A report from the Scandanavian Mycosis Fungoides Group. Acta Derm. Venereol. 1989; 69: 536-8.
19. Knobler R, Trautinger F, Radaszklewicz T, Kokoschka EM, Micksche M, Treatment of cutaneous T-cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids. J. Am. Acad. Dermatol. 1991; 24: 247-52.
20. Duvic M, Lemak NA, Redman JR, Eifel P, Tucker SL, Cabanillas FF, Kurzrock R, Combined modality therapy for cutaneous T cell lymphoma. J. Am. Acad. Dermatol. 1996; 34: 1022-9.
21. Zachariae H, Grunnet E, Thestrup-Pederson R, Molin L, Schmidt H, Starfelt GF, Thomsen K. Oral retinoid in combination with bleomycin, cyclophosphamide, prednisone and transfer factor in mycosis fungoides. Acta Derm. Venereol. 1982; 62: 162-4.
22. Miller VA, Benedetti FM, Rigas JR, Verret AL, Pfister DG, Straus D, Kris MG, Crisp M, Heyman R, Loewan GR et al. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J. Clin. Oncol. 1997; 15; 790-5.
23. 389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 1998; 91: 399-405.
24. Rook AH, Wood GS, Yoo EK, Elenitsas R, Rao DMF, Sherman ML et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999; 94: 902-8.
25. Lundin J, Osterborg G, Brittinger G, Crowther D, Dombret H, Engert A et al. CAMPATH-1H monoclonal antibody in the therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study. J. Clin. Oncol. 1998; 16: 3257-63.
26. Nagpal S, Athanikar J, Chandraratna RAS. Separation of transactivation and AP1 antagonism functions of retinoic acid receptor alpha. J. Biol. Chem. 1995; 270: 923-7.
27. Boehm MF, Zhang L, Badea BA, White SK, Mais DE, Berger E, Suto CM, Goldman ME, Heyman RA. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J. Med. Chem. 1994; 57: 2930-41.
28. Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S et al. EORTC classification for primary cutaneous lymphoma: A proposal from the cutaneous lymphoma study group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90; 354-71.
29. Myskowski P, Washenik K, Stevens V, Yocum R. A composite assessment method for evaluating CTCL. J. Invest. Dermatol. 2000; 114: 840.
30. Smith EL, Pincus SH, Donovan L, Hollck MF. A novel approach for the evaluation and treatment of psoriasis. Oral or topical use of 1,25-dihydroxyvitamin D3 can be safe and effective therapy for psoriasis. J. Am. Acad. Dermatol 1988; 19: 516-28.
31. Karnofsky DA. Meaningful clinical classification of therapeutic responses to anticancer drugs. Clin. Pharmacol. Ther. 1961; 2: 709-12.
32. Chua SL, Seymour JF, Prince HM. Deafness from eighth cranial nerve involvement in a patient with large-cell transformation of mycosis fungoides. Eur. J. Haematol. 2000; 64: 340-3.
33. Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlaka P, Duvic M. Central hypothyroidism associated with retinoid X receptor-selective ligands. N. Engl. J. Med. 1999; 340: 1075-9.